# Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29)

> **NCT06621459** · — · RECRUITING · sponsor: **University Hospital, Brest** · enrollment: 30 (estimated)

## Conditions studied

- Brest Cancer
- Abemaciclib
- Adjuvant Therapy
- Antineoplastic Combined Chemotherapy Protocols
- Breast Neoplasms

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06621459
- **Lead sponsor:** University Hospital, Brest
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-26
- **Primary completion:** 2025-10-31
- **Final completion:** 2025-10-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06621459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06621459, "Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT06621459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*